Search

New initiative elevates the importance of CKD testing

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

More Health: For People & Animals

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Our Culture of Caring: Volunteering

At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US

Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

Boehringer Ingelheim announces InPedILD PhaseIII trial results

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US

Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

Our people

Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Patients with a rare and aggressive form of liposarcoma need treatment advances

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

Discover your hidden talent with BI Open – the new platform for data science enthusiasts

Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Propeller Health & BI Announce New Partnership | BI US

Propeller Health, the leading digital health solution for respiratory medicine and BI announce new partnership to help people living with COPD & asthma.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers